| With the eventa (n = 41) | Without the eventb (n = 78) | p |
---|---|---|---|
Age, years, mean ± SD | 72.6 ± 8.3 | 73.3 ± 7.3 | 0.622 |
Female patients, % | 73.2 | 64.1 | 0.317 |
Weight, kg, mean ± SD | 49.4 ± 9.2 | 52.5 ± 11.1 | 0.128 |
Signs and symptoms of cranial lesions at baseline, % | 65.9 | 83.3 | 0.03 |
 Headache, % | 51.2 | 64.1 | 0.173 |
 Abnormal temporal artery, % | 51.2 | 64.1 | 0.173 |
 Jaw claudication, % | 36.6 | 32.1 | 0.619 |
 Visual disturbance, % | 19.5 | 25.6 | 0.454 |
LVLs detected by imaging at baseline, % | 78.0 | 46.2 | 0.001 |
 Any lesions of the aortic branchesc, % | 48.8 | 37.2 | 0.222 |
 Any lesions of the aortad, % | 53.7 | 30.8 | 0.015 |
 Any structural vascular damagee, % | 31.7 | 19.2 | 0.127 |
 Stenosis of the aortic branchesc, % | 12.2 | 15.4 | 0.637 |
 Aneurysm of the aorta, % | 9.8 | 2.6 | 0.106 |
Fever at baseline, % | 24.4 | 36.8 | 0.170 |
Polymyalgia rheumatica at baseline, % | 43.9 | 41.0 | 0.763 |
CRP at baseline, mg/dl, median (interquartile range) | 7.15 (3.75–11.1) | 6.82 (2.99–11.2) | 0.810 |
Ischemic heart disease at baseline, % | 2.4 | 7.7 | 0.235 |
Cerebrovascular disease at baseline, % | 17.1 | 11.5 | 0.400 |
Hypertension at baseline, % | 39.0 | 44.9 | 0.540 |
Diabetes mellitus at baseline, % | 19.5 | 17.9 | 0.835 |
Hyperlipidemia at baseline, % | 22.0 | 29.5 | 0.378 |
Initial dose of PSL, mg/kg/day, mean ± SD | 0.76 ± 0.26 | 0.75 ± 0.22 | 0.799 |
PSL dose at week 4, mg/kg/day, mean ± SD | 0.57 ± 0.20 | 0.56 ± 0.16 | 0.652 |
PSL dose at week 8, mg/kg/day, mean ± SD | 0.42 ± 0.16 | 0.41 ± 0.14 | 0.774 |
PSL dose at week 12, mg/kg/day, mean ± SD | 0.36 ± 0.15 | 0.34 ± 0.11 | 0.364 |
Immunosuppressive drug use at baseline, % | 15.0 | 9.0 | 0.245 |
Immunosuppressive drug use during observational period, % | 75.6 | 28.2 | < 0.001 |
 MTX for induction therapy, n (%) | 11 (26.8) | 9 (11.5) | – |
 MTX for flare, % | 12 (29.3) | – | – |
 CY for induction therapy, % | 2 (4.9) | 2 (2.6) | – |
 CY for flare, % | 3 (7.3) | – | – |
 AZA for induction therapy, % | 7 (17.1) | 4 (5.1) | – |
 AZA for flare, % | 2 (4.9) | – | – |